The target for the IndiTreat® mCRC Start test is patients with newly diagnosed metastatic colorectal cancer (synchronous metastases) or previously treated localized disease with new onset of metastases (metachronous metastases). The aim of drug treatment is to downsize metastases to make them operable, or palliative to extend survival and / or improve quality of life.
Patients with metastases not suited for primary surgery are offered first line systemic therapy. The chemotherapy options are typically a cytotoxic doublet such as FOLFOX or FOLFIRI or, in very selected patients the cytotoxic triplet FOLFOXIRI or the monotherapy fluorouracil. In practice, most patients are treated with FOLFOX or FOLFIRI in first line and when the disease progresses, the “opposite” regimen is used in second line.
The average treatment outcome of FOLFOX and FOLFIRI in first line is comparable with a response rate of 55%, Progression-Free Survival of 8 months and Overall Survival following a “continuum of care” of nearly 3 years. However, patients respond differently to FOLFOX and FOLFIRI, and data suggests that getting the right treatment sequence (FOLFOX followed by FOLFIRI vs. FOLFIRI followed by FOLFOX) for an individual patient may double survival length compared to getting the opposite sequence. The challenge is that there are no biomarkers to predict this response.
VALUE OF GUIDED TREATMENT
The unique value of the IndiTreat® Start test is that the individual patient response to the different drug regimens is predicted based on tumoroids created from the patient’s own tumoral cells. This is of major importance because getting the right therapy as the first step increases the patient’s chances that operation becomes possible, or significantly longer Progression-Free and Overall Survivals are achieved.
|IndiTreat® mCRC Start – DRUG PANEL|
|Ordering Code: 2CX-01-CRC-02|